• Packaging Pharmaceuticals With Low Humidity And/Or Low Oxygen Requirements

    The onus is on manufacturers and their contract partners to deliver a safe, pure, effectively packaged drug. To identify protective packaging materials and to ensure that drug products are packaged in an environment with the appropriate humidity and oxygen levels, pharmaceutical contract packagers will need to understand all the implications of those parameters to implement an appropriate packaging and handling strategy.

  • Accelerating cGMP Production Using Rapid Tech Transfer

    The result of a recent partnership between Cytiva and Teva Pharmaceuticals is evidence that a successful tech transfer is possible only with effective communication, diligent project management, and a wide range of expertise.

  • Rentschler Biopharma Corporate Presentation

    We empower our clients to help patients with serious or rare diseases. With our dedication and expertise, we convert medical research into outstanding biopharmaceuticals.

  • Orphan Drugs: Balancing Financial Incentives & Complex Challenges

    Orphan drugs are notorious for their high costs and risk factors, which is attributed to smaller patient pools and higher development and launch costs. Despite the niche, high risk market, orphan drugs are on the rise because of the financial incentives and benefits companies are receiving for new drug development. Whether your orphan drug is a small or large molecule, there are key strategies that you can adopt to enable a seamlessly transition from early development into commercial manufacturing, while also balancing your investment.

  • Lung Cancer Treatment By Inhaled Formulations

    Explore formulation and manufacturing considerations for development of dry-powder therapeutics, including a case study where topotecan is formulated for DPI administration to the lung.

  • Achieving Business Continuity In Pharma During COVID-19 Restrictions

    To ensure business continuity during COVID-19 restrictions, we developed a virtual factory acceptance testing solution that allowed SaudiVax to advance their manufacturing plan.

  • Navigating The Adoption Of Continuous Pharma Manufacturing

    Driving a path forward for continuous manufacturing calls for a closer look at current global challenges, any existing barriers, and the ideas and initiatives necessary to fulfill its potential.

  • How To Prepare For Future Viral Vector Manufacturing Technologies And Platforms

    The challenges and shortage of vector production reflect the fact that these materials and products are having such strong clinical success. Let’s celebrate the reason for this demand. To meet it, we need to industrialize and rethink how we transition from what has historically been carried out in translational clinical centers at smaller scale, using flasks and open systems, towards commercial production and methodologies.

  • Agile, Cost Effective Lyophilization Cycle Development

    Lyophilization can be expensive and time-consuming. Our lyophilization capabilities deliver cost-effectiveness, agility, and superb data-capture, and your lyophilization cycle development will be done by experienced, skilled research and development scientists.


  • Bringing Covid-19 therapeutic solutions to the clinic and market with speed, precision and scalability is now a challenge with unparalleled consequence. Ajinomoto Bio-Pharma Services remains committed to helping customers address the global demand for a solution.

  • Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.

  • Managing disparate data across global manufacturing networks makes capturing, analyzing and sharing process data complex. Skyland PIMS cloud-based, data collaboration platform provides a quick-to-implement, low-cost and high-value solution without the need for enterprise IT infrastructure.

  • When it comes to HPAPI, you will notice that we operate with a quiet confidence that comes from years of experience with HPAPI and cytotoxic drug products. At Pii we have learned that every successful HPAPI project begins with a deep understanding of the data.

  • We offer a unique range of formulation and aseptic filling in vials, prefilled syringes, or cartridges to address production needs that span from small early-stage clinical products to larger-scale commercial products.